CG Oncology, Inc. Quick Ratio
The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.
- CG Oncology, Inc. quick ratio for the quarter ending 2026-06-30 was 21.77, a 0.04% increase year-over-year.
- CG Oncology, Inc. quick ratio for the quarter ending 2026-03-31 was 30.56, a 0.51% increase year-over-year.
- CG Oncology, Inc. quick ratio for the quarter ending 2025-12-31 was 24.07, a 30.69% decline year-over-year.
- CG Oncology, Inc. quick ratio for the quarter ending 2025-09-30 was 22.28, a 35.59% decline year-over-year.
- CG Oncology, Inc. quick ratio for fiscal 2025 was 24.07, a 30.69% decline from fiscal 2024.
- CG Oncology, Inc. quick ratio for fiscal 2024 was 34.72, a 163.74% increase from fiscal 2023.
- CG Oncology, Inc. quick ratio for fiscal 2023 was 13.17.
- Available history
- 2023-12-31 to 2026-06-30
- Data captured
Historical Quick Ratio
Annual Quick Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |